BridgeBio Oncology Therapeutics Inc. (BBOT), a clinical-stage biopharmaceutical company, on Tuesday presented preclinical data evaluating BBO-10203 in blocking interactions between RAS an PI3Ka in tumors at the 2026 annual meeting of the American Association of Cancer Research (AACR).
BBO-10203 is an orally bioavailable small molecule drug, developed to inhibit RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia by blocking physical interactions between RAS and PI3Ka. The protein-protein inhibitor binds to the RAS-binding domain of PI3Ka, preventing its activation by the KRAS, HRAS, and NRAS oncogenes, thus reducing downstream signaling and tumor growth.
The company reported preclinical data that indicated that BBO-10203 can block interactions between RAS and PI3Ka without blocking the kinase activity of PI3Ka. The drug's action was consistent independent of mutations on RAS and PI3Ka, indicating a larger potential patient population.
Preclinical testing in HER2AMP breast cancer cell lines showed that PI3Ka activity was dependent on RAS. BBO-10203 induced tumor regression at 30 mg/kg QD, and no hyperglycemia was observed at 100 mg/kg QD. When tested in combination with HER2-targeted therapies tucatinib and trastuzumab, the drug showed strong activity in HER2AMP in vivo models.
BBO-10203 is currently in the Phase 1 BREAKER-101 trial for the treatment of HER2+ breast cancer, HR+/HER2 breast cancer, KRAS-mutant colorectal cancer, and KRAS-mutant non-small cell lung cancer (NSCLC).
BBOT closed Tuesday at $9.46, up 2.16%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.